scholarly journals The success of treatment of chronic hepatitis C in opiate addicts in Clinical center of Vojvodina

2014 ◽  
Vol 67 (3-4) ◽  
pp. 123-130
Author(s):  
Milica Odavic ◽  
Tomislav Preveden
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Successful Treatment ◽  
Standard Therapy ◽  
Drug Users ◽  
Intravenous Drug ◽  
Intravenous Drug Users ◽  
Clinical Center

Introduction: Chronic hepatitis C is a disease with a high prevalence in the population of intravenous drug users. Serious clinical course of the disease, which can lead to cirrhosis of the liver with all its complications, has a large epidemiological and clinical significance. This study was aimed at assessing the success of antiviral treatment of chronic hepatitis C in intravenous drug users and defining indicators of successful treatment in this population. Materials and Methods. This retrospective study included 316 patients treated with standard therapy for chronic hepatitis C, pegylated interferon and ribavirin, at the Department of Infectious Diseases, Clinical Center of Vojvodina in Novi Sad in the period from January 2007 to December 2012. The patients were divided into a group of intravenous drug users (n = 163) and a group of other modes of transmission of hepatitis C virus (n = 153). The indicators of successful treatment were measured in both groups. Results. A total 51.57% of the subjects belonged to the group of intravenous drug users. The therapy was successful in 87.15% of cases, while the success was achieved in only 53.47% of cases in the group of patients infected otherwise. The positive effect of therapy was associated with younger age, shorter duration of infection, low levels of fibrosis and a higher percentage of infected with hepatitis C virus genotypes 2 and 3. Conclusion. The population of intravenous drug users can be effectively treated with the standard therapy for chronic hepatitis C, even more successfully than the population infected in some other way.

Compliance and effect of treatment for chronic hepatitis C (CHC) in intravenous drug users (IVDUS)

2003 ◽  
Vol 38 ◽  
pp. 165 ◽  
Author(s):  
G. Robaeys ◽  
H. Van Vlierberghe ◽  
C. Mathei ◽  
M. Van Ranst ◽  
L. Bruckers ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Intravenous Drug ◽  
Intravenous Drug Users ◽  
Effect Of Treatment

scholarly journals The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia

PeerJ ◽  
2016 ◽  
Vol 4 ◽  
pp. e2576 ◽  
Author(s):  
Zoran Bogdanović ◽  
Ivana Marinović-Terzić ◽  
Sendi Kuret ◽  
Ana Jerončić ◽  
Nikola Bradarić ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Intravenous Drug ◽  
Response To Treatment ◽  
Study Cohort ◽  
Intravenous Drug Users ◽  
Hepatitis C Infection ◽  
The Impact

Background Several genes and their single nucleotide polymorphisms (SNPs) are associated with either spontaneous resolution of hepatitis C infection or better treatment-induced viral clearance. We tested a cohort of intravenous drug users (IVDU) diagnosed with chronic hepatitis C virus (HCV) for treatment response and its association with the SNPs in the interleukin-6 (rs1800795-IL6) and the interleukin-28B (rs12979860-IL28B) genes. Methods The study included 110 Croatian IVDU positive for anti-HCV antibody. Genotyping was performed by polymerase chain reaction (PCR) based approach. Patients were treated by standard pegylated-interferon/ribavirin and followed throughout a period of four years, during which sustained virological response (SVR) was determined. All data were analysed with statistical package SPSS 19.0 (IBM Corp, Armonk, NY, USA) and PLINK v1.07 software. Results Patients showed a significantly better response to treatment according to the number of copies of the C allele carried at rs1800795-IL6 (P = 0.034). All but one of the patients with CC genotype achieved SVR (93%), whereas the response rate of patients with GG genotype was 64%. The association of rs1800795-IL6 with SVR status remained significant after further adjustment for patients’ age, fibrosis staging, and viral genotype (OR 2.15, 95% CI 1.16–4.68, P = 0.019). Distributions of allele frequencies at the locus rs12979860-IL28B among the study cohort and the underlying general population were suggestive of a protective effect of CC genotype in acquiring chronic hepatitis C in the Croatian IVDU population. Discussion The rs1800795-IL6 polymorphism is associated with positive response to treatment in IVDU patients positive for HCV infection. A protective role of rs12979860-IL28B CC genotype in acquiring chronic hepatitis C is suggested for Croatian IVDU population.

Intravenous drug users and chronic hepatitis C

2009 ◽  
Author(s):  
Graham R. Foster ◽  
Giorgio Barbarini ◽  
Raffaella Brigada ◽  
Olav Dalgard ◽  
Philip Bruggmann ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Intravenous Drug ◽  
Intravenous Drug Users

Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case–control study

AIDS ◽  
2001 ◽  
Vol 15 (15) ◽  
pp. 2011-2016 ◽  
Author(s):  
Lawrence Serfaty ◽  
Dominique Costagliola ◽  
Dominique Wendum ◽  
Odile Picard ◽  
Marie-Caroline Meyohas ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Hiv Infection ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Case Control Study ◽  
Case Control ◽  
Intravenous Drug ◽  
Intravenous Drug Users ◽  
Control Study

scholarly journals Characteristics of Chronic Hepatitis C Among Intravenous Drug Users: A Comparative Analysis

2010 ◽  
Vol 10 (2) ◽  
pp. 153-157 ◽  
Author(s):  
Maja Jovanović ◽  
Branislav Jovanović ◽  
Milena Potić ◽  
Ljiljana Konstantinović ◽  
Miodrag Vrbić ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Drug Use ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Combined Treatment ◽  
Intravenous Drug ◽  
Therapy Outcome ◽  
Control Group ◽  
Intravenous Drug Users

Hepatitis C virus (HCV) usually evades the host’s immune system and persists as a chronic infection. Intravenous drug users (IVDU) represent the majority of patients infected with HCV Combined therapy of chronic hepatitis C (CHC) with peginterferon a-2a and ribavirin can be successful even when patients continue the intravenous drug use. In this study, we compared the characteristics of age, gender, genotype, and stage of fibrosis and the therapy outcome among IVDU and patients with no history of drug use. The study included 69 patients diagnosed with chronic hepatitis C, evaluated and treated at the Clinic for infectious diseases in Nis from 2005 to 2009. HCV RNA was detected by a polymerase chain reaction and the determination of genotypes was undertaken. Liver biopsies were examined histopathologicaly. Patients received a combined treatment of peginterferon alfa-2a and ribavirin. Therapy efficiency was evaluated based on the achievement of the sustained virological response (SVR). A comparison of characteristics was performed with the use of Mann-Whitney U test, chi-square (χ2) test and logistic regression. IVDU were significantly younger than patients in the control group. Prevalence of stage 1 fibrosis was significantly higher among IVDU. The therapy outcome is influenced by the patient’s age and HCV genotypes. Each year added to one patient decreased the therapy efficiency by 8.1%, while genotypes 2 and 3 experienced a therapy which was 2.08 times more efficient than in other cases. IVDU represent a specific population different from non-using patients. However, they can be treated effectively if an adequate patient-doctor relationship is established.

Sign in / Sign up

Export Citation Format

Share Document